PitchBook clients can access the complete Excel data pack via the Research Center on the PitchBook Platform.
Medtech IPO momentum builds as BillionToOne makes debut, Medline next in line
The medtech sector cooled off in Q3 after a strong first half, trailing broader market gains as investors favored AI-heavy names and cyclical growth sectors. Even still, despite macroeconomic headwinds and tariff uncertainty, select firms including Tempus AI, Thermo Fisher, and Labcorp all posted double-digit gains.
On the private markets front, IPO momentum is returning with BillionToOne’s successful listing marking a key milestone for the sector. Medline is now next in line following Caris Life Sciences’ earlier debut this year. Sector fundamentals remain resilient with most medtech firms performing well, but growth is expected to normalize heading into 2026 and 2027. The life sciences sector finally appears set for recovery as post-pandemic realignment and cost discipline begin to drive renewed demand.